The authors used the Decipher GRID platform (Veracyte, Inc., San Francisco, CA, USA) to perform biomarker analyses among samples collected at screening among patients in the ENACT trial.
Among 258 genomic signatures, 108 with significant interactions were evaluated. In particular, the authors used:
- the Decipher classifier to assess for correlation with therapeutic disease progression;
- classifiers of androgen-receptor activity (AR-A) and PAM50 to assess for correlation with negative biopsies at year 2.
Statistical analysis was conducted by Cox proportional hazards models for disease progression, logistic regression (AR-A), and Fisher’s exact test (PAM50) for negative biopsy. Univariable and multivariable analyses were performed.
The authors examined 95 samples among 46 patients who received active surveillance along and 49 who received enzalutamide. Among all patients, the Decipher classifier was prognostic for therapeutic disease progression (HR 1.45; 95% CI 1.04, 2.02; p=0.04). Additionally, both a high AR-A and luminal PAM50 classification were predictive of response to enzalutamide.
Dr. Ross, therefore, concluded that biomarker signatures were associated with overall disease progression as well as predictive of the benefit of enzalutamide in patients undergoing active surveillance.
Presented by: Ashley Ross, MD, Ph.D., Associate Professor, Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IllinoisWritten by: Christopher J.D. Wallis, University of Toronto Twitter: @WallisCJD during the 2022 European Society of Medical Oncology (ESMO) Annual Hybrid Meeting, Paris, FR, Fri, Sept 9 – Tues, Sept 13, 2022.